FMP
Vaxcyte, Inc.
PCVX
NASDAQ
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company also develops VAX-XP to protect against emerging strains and address antibiotic resistance; VAX-A1, a conjugate vaccine candidate designed to treat Group A Strep; and VAX-PG, a novel protein vaccine candidate targeting keystone pathogen responsible for periodontitis. The company was formerly known as SutroVax, Inc. and changed its name to Vaxcyte, Inc. in May 2020. Vaxcyte, Inc. was incorporated in 2013 and is headquartered in San Carlos, California.
74.37 USD
1.35 (1.82%)
Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
2.76B
1.76B
1.57B
1.39B
1.38B
1.18B
1B
853.43M
727.07M
619.42M
Revenue %
-
-36.34
-10.71
-11.56
-0.61
-14.81
-14.81
-14.81
-14.81
Operating Cash Flow
134.53M
19.82M
-133.01M
76.93M
62.37M
17.84M
15.2M
12.95M
11.03M
9.4M
Operating Cash Flow %
4.87
1.13
-8.47
5.54
4.52
1.52
1.52
1.52
1.52
Cap Ex
-33.71M
-36.27M
-27.65M
-23.55M
-23.6M
-19.87M
-16.93M
-14.42M
-12.29M
-10.47M
Cap Ex %
-1.22
-2.06
-1.76
-1.7
-1.71
-1.69
-1.69
-1.69
-1.69
Free Cash Flow
100.82M
-16.45M
-160.66M
53.38M
38.77M
-2.03M
-1.73M
-1.47M
-1.26M
-1.07M
Weighted Average Cost Of Capital
Price
1.91
Beta
Diluted Shares Outstanding
32.56M
Costof Debt
10.51
Tax Rate
After Tax Cost Of Debt
10.51
Risk Free Rate
Market Risk Premium
Cost Of Equity
Total Debt
366.79M
Total Equity
62.19M
Total Capital
428.98M
Debt Weighting
85.5
Equity Weighting
14.5
Wacc
9.25
Build Up Free Cash Flow
Year
2020
2021
2022
2023
2024
2025
2026
2027
2028
2029
Revenue
2.76B
1.76B
1.57B
1.39B
1.38B
1.18B
1B
853.43M
727.07M
619.42M
Operating Cash Flow
134.53M
19.82M
-133.01M
76.93M
62.37M
17.84M
15.2M
12.95M
11.03M
9.4M
Cap Ex
-33.71M
-36.27M
-27.65M
-23.55M
-23.6M
-19.87M
-16.93M
-14.42M
-12.29M
-10.47M
Free Cash Flow
100.82M
-16.45M
-160.66M
53.38M
38.77M
-2.03M
-1.73M
-1.47M
-1.26M
-1.07M
Wacc
9.25
9.25
9.25
9.25
9.25
Pv Lfcf
-1.86M
-1.45M
-1.13M
-881.81k
-687.64k
Sum Pv Lfcf
-6.01M
Terminal Value
Growth In Perpetuity Method
Long Term Growth Rate
Wacc
9.25
Free Cash Flow T1
-1.09M
Terminal Value
-15.06M
Present Terminal Value
-9.67M
Intrinsic Value
Enterprise Value
-15.68M
Net Debt
325.52M
Equity Value
-341.2M
Diluted Shares Outstanding
32.56M
Equity Value Per Share
-10.48
Projected DCF
-10.48 1.182%
